In a major development for the vaccination drives ongoing in various nations across the world, Finland's medical agency has received the first report of an adverse reaction to the COVID-19 vaccine developed by the United States (US) based pharmaceutical major Pfizer and German BioNTech, Livemint.
This comes just a week after Europe began its mass immunisation drive on 27 December following the authorisation provided by the European Commission. However, no information has been revealed about the nature of the adverse reaction reported.
The Finnish agency's Chief Physician Maija Kaukonen has said that the agency would make the information about the reaction available on its website once there are at least five such reports. She also added that the reports of allergic or adverse reactions were likely to increase.
Kaukonen refused to share any further details citing patient confidentiality.
Pfizer and BioNTech's vaccine has also applied for an emergency use authorisation in India. It had placed its papers before the authorities in December. Meanwhile, the authorities have accorded the emergency use authorisation to the Covaxin and Covishield vaccines in India.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.